Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totaling 4,454 shares, an increase of 1,266.3% from the December 15th total of 326 shares. Based on an average daily volume of 825,551 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the shares of the company are sold short. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 825,551 shares, the short-interest ratio is presently 0.0 days.
Daiichi Sankyo Price Performance
Daiichi Sankyo stock traded up $0.07 during midday trading on Monday, hitting $23.06. 501,925 shares of the company’s stock were exchanged, compared to its average volume of 360,220. The company has a market cap of $43.68 billion and a P/E ratio of 21.75. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.60 and a current ratio of 2.31. The stock has a 50-day moving average price of $22.37 and a two-hundred day moving average price of $23.72. Daiichi Sankyo has a 52-week low of $20.51 and a 52-week high of $29.68.
Wall Street Analyst Weigh In
Separately, Zacks Research lowered Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a report on Wednesday, November 19th. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy”.
Daiichi Sankyo Company Profile
Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.
Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.
Further Reading
- Five stocks we like better than Daiichi Sankyo
- Which stock will the White House buy next?
- A month before the crash
- How a Family Trust May Be Able To Help Preserve Your Wealth
- If You Keep Cash In A U.S. Bank Account… Read This NOW
- The $100 Trillion AI Story No One Is Telling You
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.
